Haleon, the consumer healthcare company behind brands like Sensodyne and Centrum, saw its stock price plummet 5.05% in intraday trading on Thursday. This sharp decline came after the company's revenue growth forecast for 2025 fell short of analysts' expectations.
According to Haleon's guidance, the company expects organic revenue growth of 4% to 6% for the year 2025, lower than the consensus estimate of 5.3%. While the company reported solid fourth-quarter results and full-year revenue of £11.23 billion, in line with expectations, investors seemed concerned about the potential slowdown in growth.
Analysts at Jefferies acknowledged the strong fourth-quarter sales but noted that the company's "broad outlook commitment" overshadowed these positive results. They described Haleon's forecast as "wise" given the ongoing uncertainties, but it appears that the market had higher expectations for the company's revenue growth trajectory.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。